Mar. 2, 2026
Compass Diversified Focuses on Stabilizing Operations, Reducing Debt
Company outlines plans to sell subsidiaries, rebuild investor confidence after 'difficult' 2025
Mar. 2, 2026
SES Reports Revenue, EBITDA Shortfall in 2025 After Intelsat Acquisition
Growth expected to return in 2027 after short-term integration challenges.
Feb. 28, 2026
Xometry CFO Sells $656K in Company Stock
James Miln, the Chief Financial Officer of Xometry, sold over 15,000 shares of the company's stock.
Feb. 28, 2026
Compass Diversified Outlines Deleveraging Plan After 'Difficult' 2025
Company aims to reduce leverage, rebuild investor confidence, and 'reignite' acquisition strategy when conditions allow
Feb. 27, 2026
Xometry CTO Sells $198,607 in Stock
Vaidyanathan Raghavan, the Chief Technology Officer of Xometry, has sold a portion of his shares in the company.
Feb. 27, 2026
Novavax Shifts Focus to Partnerships and R&D
Biotech company reduces operating expenses and stabilizes balance sheet as it advances early-stage pipeline and explores new Matrix-M adjuvant applications.
Feb. 26, 2026
Emergent BioSolutions swings to $52.6M 2025 profit
Despite a 29% revenue drop to $742.9M, Emergent delivered $205M in adjusted EBITDA, swung to $52.6M net income and repaid $100M of term loan debt.
Feb. 22, 2026
Saul Centers Expected to Report Earnings on Friday
Real estate investment trust Saul Centers to release Q4 2025 financial results.
Feb. 19, 2026
JBG Smith Properties Reports Q4 Earnings
Real estate investment trust posts funds from operations of $9.9 million
Feb. 15, 2026
Federal Realty Investment Trust Reports Strong Q4 and Full-Year 2025
REIT highlights solid leasing, active investment and disposition activity, and 2026 guidance reflecting continued momentum
Feb. 13, 2026
Federal Realty Investment Trust Reports Strong Q4 and Full-Year 2025 Results
Company highlights solid leasing, active investment and disposition activity, and 2026 guidance that reflects continued momentum despite refinancing headwind.
Feb. 10, 2026
Charlie's Holdings Selected for FDA Premarket Tobacco Product Applications Meeting
Company's Board Member, Dr. Ed Carmines, to Serve as Panelist at Prestigious FDA Roundtable
